LAM/TSC Seminar Series
May 27, 2010
PTEN Syndromes and LAM
Speaker: Ramon Parsons, MD, PhD, Columbia University/ Herbert Irving Comprehensive Cancer Center/ Institute for Cancer Genetics
April 01, 2010
"Uterine Leiomyoma and LAM"
Speaker: Cheryl Walker, PhD, University of Texas MD Anderson Cancer Center
Speaker: Cynthia Morton, PhD, HMS / Brigham and Women's Hospital
Speaker: Jonathan Fletcher, MD, HMS / Brigham and Women's Hospital
March 04, 2010
Presenter: Katrin Duevel, PhD
Topic: A metabolic gene regulatory network downstream of TSC and mTORC1
Presenter: June Goto, PhD
Topic: Regulable loss of Tsc1 in neural progenitor cells yields a model of tuberous sclerosis complex (TSC)
with giant cells and other features replicating cortical tubers
Presenter: Sean Hasso, PhD
Topic: mTOR independent roles for TSC1/TSC2 during zebrafish development
Presenter: Yonghao Yu, PhD
Topic: Identification and Characterization of Novel Downstream Effectors of the mTORC1 Signaling Pathway
Using Quantitative Mass Spectrometry
February 11, 2010
"Hormonal Therapy and Relevant Trials in LAM"
Speaker: Sergio Harari, MD
Discussant: Joel Moss, MD, PhD and Steven Come, MD
January 14, 2010
"Lung Regeneration For Adults Only: Age and Matrix Dependence of Lung Responses to Pneumonectomy in New Animal Models"
Speaker: Andrew Hoffman, DVM, DVSc, DACVIM
Discussant: Hilary Goldberg, MD
November 12, 2009
LAM/TSC Post-Doctoral/Graduate Student International Poster
We are pleased to invite you to view and interact with 14 poster presenters working to advance LAM and TSC research on November 12, 2009 in NRB 350 at Harvard Medical School or via live webcast. Please join us for presentations, star PI-judging and announcement of cash prize winners!
October 22, 2009
Functionalizing the Cancer Genome
Dr. Lynda Chin is a Professor of Dermatology at the Harvard Medical School and Department of Medical Oncology at Dana-Farber Cancer Institute as well as an associate member of the Broad Institute of MIT and Harvard. Dr. Chin also co-leads the DF/HCC Melanoma Program and is the Scientific Director of the Belfer Institute for Applied Cancer Sciences at DFCI, which has recently entered into a novel academic-corporate alliance with MERCK Pharmaceuticals to co-develop cancer therapeutics. Dr. Chin co-founded AVEO Pharmaceuticals in 2002, a cancer biotechnology company that emphasizes cancer biology. Most recently, Dr. Chin also founded Metamark Genetic, a cancer diagnostic company that will develop function-based prognostic determinants that can guide customized management of early-staged cancer patients.
Elizabeth (Lisa) Henske, MD, Director of Center for LAM Research and Clinical Care Center at Brigham and Women's Hospital.
October 1, 2009
Breakthrough microchip technology to help detect and capture circulating tumor cells and work-in-progress focused on optimizing that technology for use in LAM patients
Mehmet Toner, PhD - Professor of Surgery at Massachusetts General Hospital (MGH) and Harvard Medical School, and a faculty member at the Harvard-MIT Division of Health Sciences and Technology. He is the principal investigator and serves as the Director of the BioMicroElectroMechanical Systems Resource Center at MGH.
Sunitha Nagrath, PhD - Instructor in Surgery at Massachusetts General Hospital and BioMicroElectroMechanical Systems Resource Center at MGH.
May 28, 2009
Geraldine Finlay, MD - LAM: A Disease That Affects Young Females In Their Reproductive Years.. Or Is It?
Reuben Shaw, PhD - AMPK Regulation of mTOR Signaling: Possible Use Of Existing Diabetes Drugs As Therapeutics For TSC - Tumors?
April 30, 2009
Pathways Regulating Neural Crest Development and Melanoma
Leonard Zon, MD - Department of Pediatrics, Harvard Medical School Director, Children's Hospital Boston Stem Cell Program DF/HCC
Elizabeth Petri Henske, MD
March 5, 2009
Lymphangiogenesis in Development and Disease
Kari Alitalo, MD, PhD - Academy Professor Molecular Cancer Biology Program,University of Helsinki, Finland
Caroline Heckman, PhD - Researcher University of Helsinki, Finland
February 5th, 2009
mTOR Inhibitor Therapy of Neurologic Manifestations of Tuberous Sclerosis
Speaker: David Franz, MD, Director, Tuberous Sclerosis Clinic, Cincinnati Children's Hospital
Discussant: Mustafa Sahin, MD, PhD, Director, Multidisciplinary Tuberous Sclerosis Program, Children's Hospital Boston
January 15, 2009
The winners from the November 6th, 2008 Poster Session present their winning posters
Shomit Sengupta - MIT/ Sabatini Lab
Jane Yu, PhD - Harvard Medical School/ Brigham and Women's Hospital
Greg Hoffman, PhD - Harvard Medical School/ Blenis Lab
Jun Kawasaki - Harvard Medical School/ Children's Hospital - Chan Lab
December 11, 2008
Developing Chemical Probes for the Genome and New Therapeutic Targets for LAM, TSC and Other Neglected Diseases: Studies From the NIH Chemical Genomics Center
Speaker: Christopher Austin, MD (NIH-NHGRI)
Discussant: Lewis Cantley, PhD (HMS/BIDMC)
November 6, 2008
LAM/TSC Seminar Series In Person and Virtual Poster Session
To read more about the Poster Session, to see poster abstracts, agenda and other information click below.
Session Video Top five speakers (One virtual four in person)
Seminar Photos
October 16, 2008
Stem Cells in Normal Lung and LAM
Speaker: Craig Peacock, PhD
Discussant: Neil Watkins, MBBS, PhD
Respondent: Elizabeth Petri Henske, MD
October 2, 2008
To treat or not to treat: controversies on epilepsy "prophylaxis" in TSC
Speaker: Dr. Sergiusz Jozwiak, MD, PhD
Discussant: Elizabeth A. Thiele, MD, PhD
June 5, 2008
The VHL Tumor Suppressor Protein: Cancer and Oxygen Sensing
Speaker: William Kaelin, MD (DFCI/HMS)
Discussant: Leif Ellisen, MD, PhD (MGH Cancer Center/HMS)
May 29, 2008
TSC2 and glucose transport: Implications for treating LAM and TSC
Speaker: Ray Yeung, MD, FRCS (C), FACS (University of Washington)
Discussant: Lewis Cantley, PhD (BIDMC/HMS)
April 17, 2008
Development of novel PI3 Kinase and MTOR Inhibitor
Speaker: William Sellers, MD (Novartis)
Discussant: Matthew Kulke, MD (DFCI/HMS)
March 13, 2008
Melanocytic markers in non-melanoma malignancies: Role of the MiT transcription factor" & Why do LAM Cells express melanocytic markers?
Speakers: David Fisher, MD, PhD (MGH/HMS) & Elizabeth Henske, MD (FCCC)
Discussant: Andrew Wagner, MD, PhD (DFCI/HMS)
February 28, 2008
Molecular mechanisms and the genetics underlying the pathogenesis of human cancer.
Speaker: Pier Paolo Pandolfi, MD, PhD (BIDMC/HMS)
Discussants: Elizabeth Thiele, MD, PhD (Massachusetts General Hospital/HMS), Brendan Manning, PhD (Harvard School of Public Health)
January 24, 2008
Critical re-cap of this week's NCI/NIH-NINDS mTOR workshop & Review of NEJM articles & letters re: LAM & TSC
Speakers: Mustafa Sahin, MD, PhD; Vijaya Ramesh, PhD; David Kwiatkowski, MD, PhD; Sandra Dabora, MD, PhD; Elizabeth Thiele, MD, PhD; Po-Shun Lee, MD; Geraldine Finlay, MD
November 1, 2007
Lymphangiogenesis: the state of the art and translational medicine; & Lymphangiogenesis and Hormonal modulation in LAM
October 11, 2007
Rewiring and misfiring: Signaling defects triggered by loss of the TSC tumor suppressors
September 20th, 2007
Regulation of cell growth and protein synthesis by mTOR
June 21, 2007
Statins: Therapeutic agents for TSC2 null states
MED28 (magicin) Functions as a Transcriptional Repressor of Smooth Muscle Differentiation at the Stem Cell Level: Implications for LAM and Other Smooth Muscle Tumors
May 10, 2007
Hypoxia, Stem Cells, and Tumor Progression
Hypoxia regulation of TSC/mTOR signaling
April 12, 2007
Special Panel: Renal AMLs in LAM/TSC
What can basic science teach us about improved clinical care?
What can diagnostic dilemmas teach us about the basic science of LAM/TSC?
March 15, 2007
New Developments in the Neurobiology of the Tuberous Sclerosis Complex
Molecular Insights into the Effects of Therapy on Malignant Gliomas
February 1, 2007
New Therapeutic Targets for Combination Therapy with Rapamycin in TSC and LAM
January 18, 2007
mTOR dependent regulation of growth and metabolism: Implications for the treatment of LAM/TSC
December 14, 2006
Does Estrogen Synthesize with mTOR activation to promote LAM cell metastasis?
November 30, 2006
LAM Research: New Insights & Unanswered Questions
Dr. Joel Moss (NIH-NHLBI) discussed key challenges in research on Lymphangioleiomyomatosis (LAM). Dr Myles Brown and Dr. George Demetri discussed and facilitated exchange on topics and potential therapeutic interventions.
October 26, 2006
mTOR Function and Regulation: Implications for the treatment of Lymphangioleiomyomatosis (LAM) & Tuberous Sclerosis Complex (TSC)
Dr. David Sabatini is Associate Professor of Biology at MIT. Dr. Brendan Manning is Associate Professor of Genetics and Complex Disease at the Harvard School of Public Health.
June 22, 2006
"Signaling Biochemistry and TSC1/TSC2: The Implications for Lymphangioleiomyomatosis (LAM) and Tuberous Sclerosis Complex (TSC)"
Kun-Liang Guan, Ph.D. from the University of Michigan whose work on signaling biochemistry and TSC1/TSC2 is highly relevant to LAM/TSC will present.
Lew Cantley, Ph.D (BIDMC, HMS) who has done seminal work on P13Kinase and protein kinase signaling pathways is highly relevant to these diseases will serve as discussant and moderator.
May 18, 2006
LAM is a disease that mainly affects women. This seminar will focus on the links between estrogen and LAM.
Dr. David Kwiatkowski, MD, PhD
Myles Brown, MD (Dana-Farber/HMS) will speak about his work on estrogen in cancer and LAM.
David Kwiatkowski, MD, PhD. (BWH/Dana-Farber/HMS) will review data on estrogen in mouse models and LAM and some new results from mutational studies of TSC1/TSC2.
February 16, 2006
Cell-specific abnormalities in neurotransmitter receptor expression in TS lesions and Regulations of TSC proteins in the CNS
Dr. Jensen is a Senior Associate in Medicine at Children's Hospital Boston and Associate Professor of Neurology, Harvard Medical School Dr. Ramesh is an Assistant in Genetics, Molecular Genetics Unit MGH and Associate Professor, Dept. of Neurology HMS.
January 26, 2006
Dr. Bernardo Sabatini, MD, PhD
Dr. Elizabeth Thiele MD, PhD
Tuberous Sclerosis Complex and the Brain
Dr Thiele spoke about the neurologic involvement in TSC followed by a talk on the basic science by Dr. Sabatini, who will also facilitated discussion.
December 1, 2005
Current and future trials of mTOR inhibitors in patients with TSC and LAM
Dr. Frank McCormack
Director, Division of Pulmonary and Critical Care at the University of Cincinnati and Chair of the LAM Foundation Scientific Advisory Board
November 3, 2005
Can lessons from antiangiogenic therapy of cancer be applied to LAM?
Dr. Judah Folkman
Dr. Marsha Moses
Dr. Folkman spoke about his recent work on LAM with Dr. Marsha Moses, Associate Professor of the Department of Surgery at Harvard Medical School / Vascular Biology Program at Children's Hospital Boston
October 6, 2005
Professor at Harvard Medical School
Dr. Avruch spoke about his work on kinase signaling pathways and recent results on the Rheb-mTOR interaction.
LAM Treatment Alliance
E-mail: info@lamtreatmentalliance.org
Address: 64 Church Street, 2nd floor; Cambridge, MA 02138; USA
Phone: +1 (617) 460-7339
Fax: +1 (617) 864-0614
Sponsors, Partners and Supporters
Harvard Medical SchoolDepartment of Continuing Education
Brigham and Women's Hospital
Dana-Farber Cancer Institute
National Heart Lung and Blood Institute
MassachusettsGeneral Hospital
National Disease Research Interchange
Foley Hoag
Starbucks Coffee